5th Floor, Brigade Towers,
Financial District, Gachibowli,
Hyderabad - 500032,
The Market is segmented by Treatment Type (Chemotherapy, Target Therapy, Immunotherapy, Hormone Therapy and Other Treatment Types), Cancer Type, End-User and Geography
The Asia-Pacific cancer therapy market will show rapid growth due to the rising prevalence of cancer, growing government initiatives for cancer awareness and increasing patient assistance programs (PAPs).
Lung, stomach, colorectum, liver, and oesophagus are the most common types of cancer in China. The increasing prevalence of cancer burden and thus, cancer therapies is due to a number of factors, including population growth, ageing, environmental pollution and unhealthy dietary habits. In addition, cigarette smoking, in particular, has also continued to be prevalent in the Asia Pacific region. The rising prevalence of cancer, thus helps the market to grow over the forecast period.
There are also several awareness programs initiated across the Asia Pacific region. For instance, the Indian government has recently announced the Ayushman India National Health Security Scheme under which the patients of cancer can take advantage of up to INR 5 lakhs, admitted without hospitalization and chemotherapy, medicines and screening expenses will be covered. Hence the presence of various government initiatives to curb the increasing prevalence of cancer is expected to drive the overall growth of the market.
As per the scope of the report, cancer therapies are drugs that block the growth and proliferation of cancer, by interfering with specific molecules, such as DNA or proteins, which are involved in the growth or expansion of cancerous cells. These therapies include surgery, radiation therapy, chemotherapy, immunotherapy, etc.
|By Treatment Type|
|Other Treatment Types|
|By Cancer Type|
|Other Cancer Types|
Report scope can be customized per your requirements. Click here.
The target therapy segment is expected to show the highest CAGR during the forecast period. The targeted therapy includes hormone therapies, gene expression modulators, apoptosis inducers, angiogenesis inhibitors, immunotherapies, signal transduction inhibitors, and toxin delivery molecules. Targeted therapy is attaining importance due to its specificity toward cancer cells while sparing the toxicity to off-target cells.
The other major factors driving the growth of the segment are an increase in R&D and the rising prevalence of various types of cancer across the globe. Targeted therapy is a treatment for cancer that is unlike the traditional chemotherapy used for cancer. The drugs for target therapy work by targeting the specific genes or proteins that are present in the cancer cells.
To understand key trends, Download Sample Report
The cancer therapy market is highly competitive and consists of several players. In terms of market share, few of the major players currently dominate the market. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence, by introducing new products with cheaper prices.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Cancer
4.2.2 Growing Government Initiatives for Cancer Awareness
4.2.3 Increasing Patient Assistance Programs (PAPs)
4.3 Market Restraints
4.3.1 High Cost of Cancer Therapies
4.3.2 Fluctuation in Reimbursement Policies
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Treatment Type
5.1.2 Target Therapy
5.1.4 Hormone Therapy
5.1.5 Other Treatment Types
5.2 By Cancer Type
5.2.1 Blood Cancer
5.2.2 Breast Cancer
5.2.3 Prostate Cancer
5.2.4 Gastrointestinal Cancer
5.2.5 Gynecologic Cancer
5.2.6 Respiratory/Lung Cancer
5.2.7 Other Cancer Types
5.3 By End-User
5.3.2 Specialty Clinics
5.3.3 Radiation Center
5.4.1 Asia Pacific
18.104.22.168 South Korea
22.214.171.124 Rest of Asia-Pacific
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.2 Astra Zeneca
6.1.3 Bayer AG
6.1.4 Bristol Myers Squibb Company
6.1.5 F. Hoffman-La Roche Ltd
6.1.6 Johnson & Johnson
6.1.7 Merck & Co. Inc.
6.1.8 Eli Lilly
6.1.9 Novartis AG
6.1.10 Pfizer Inc.
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments